Close Menu

Eli Lilly

Through the formation of the Asian Cancer Research Group, Eli Lily, Merck, and Pfizer have also committed "to create one of the most extensive pharmacogenomic cancer databases known to date."

In the latter part of December, Clinical Data’s PGxHealth division inked a research collaboration with the German Heart Institute to “conduct one of the largest retrospective case/control studies to date to validate genetic variants associated with response” to Plavix. With this study, the partners hope to further inform the clinical utility of a pharmacogenetic test in determining best-responders to the anti-platelet agent.

At a meeting hosted by the Partners HealthCare Center for Personalized Genetic Medicine last month, the events leading up to the re-labeling for colorectal cancer drugs Vectibix and Erbitux sparked discussion among participants about what Amgen and Bristol-Myers Squibb/ImClone knew about the drugs and when.

The pharmaceutical firm will have access to GeneNews' genomic biomarker program.

Medco's study will examine whether the 70 to 75 percent of patients who are "extensive metabolizers" of Bristol-Myers Squibb's Plavix will have "comparable outcomes" to patients taking Eli Lilly's more expensive Effient.

The two companies announced plans to develop a companion diagnostic to predict whether non-squamous non-small cell lung cancer patients can benefit from combination treatment with Alimta and cisplatin based on the thymidylate synthase biomarker.

Almac and Lilly will study a predictive marker for use as a companion diagnostic for a combination therapy.

Under the Phenotypic Drug Discovery program, researchers from academia or biotech submit candidate compounds in specific therapeutic areas for Lilly to evaluate and profile. Participating organizations retain full IP rights to the compounds, but Lilly receives first rights to negotiate a broader collaboration or licensing agreement.

Nanosphere will develop PGx assays to run on its Verigene SP system.

SeqWright CEO Fei Lu said this week that Lilly is one of an increasing number of pharma customers that have specifically requested sequence capture and sequencing services from the firm.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.